Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus | Zendy

Antonia GarcíaMartin | Zendy; Pedro Rozas-Moreno | Zendy; Rebeca ReyesGarcía | Zendy; Sonia Morales | Zendy; Beatriz García-Fontana | Zendy; José A. GarcíaSalcedo | Zendy; Manuel MuñozTorres | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus

Author(s) -

Antonia GarcíaMartin,

Pedro Rozas-Moreno,

Rebeca ReyesGarcía,

Sonia Morales,

Beatriz García-Fontana,

José A. GarcíaSalcedo,

Manuel MuñozTorres

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-2186

Subject(s) - sclerostin , medicine , endocrinology , bone remodeling , type 2 diabetes mellitus , glycated hemoglobin , bone mineral , femoral neck , diabetes mellitus , osteoporosis , type 2 diabetes , chemistry , biochemistry , wnt signaling pathway , gene

Diabetes mellitus is a risk factor for osteoporotic fractures. Sclerostin is an inhibitor of bone formation. However, there are no data about sclerostin levels in type 2 diabetes mellitus (T2DM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research